{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T15:30:53Z","timestamp":1648827053936},"reference-count":16,"publisher":"Institute of Biochemistry","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BIOMED KHIM"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>Physicochemical properties of the original pharmaceutical substance TST-9 based on the  3,7-diazabicyclo[3.3.1]nonane derivative with the chemical name IUPAC 6-[4methoxy-3-(1H-pyrazol-1-ylmethyl)  benzyl]-1,11-dimethyl-3,6,9-triazatricyclo[7.3.1.1]tetradecane-4,8,12-trion, were studied. TST-9 is used as an active  substance for the development of the composition and technology for the preparation of an innovative oral drug.  The pharmaceutical substance TST-9 is an amorphous white powder, odorless, soluble in chloroform, acetonitrile,  methylene chloride, acetone, dimethyl sulfoxide, dimethylformamide and alcohol, sparingly soluble in diethyl ether,  dioxane and is very slightly soluble in water, hexane, and heptane. The melting point ranged from 94\u00b0C to 96\u00b0C without  visible decomposition of the substance. The microbiological purity corresponds to category 2.2. Residual organic  solvents in the form of chloroform did not exceed 0.006%. The amount of impurities was not more than 0.15%.  The loss in mass upon drying was not more than 0.5%. The \u201cidentity\u201d was confirmed using nuclear magnetic resonance  spectroscopy and HPLC with UV detection. The data obtained in the study will contribute to the further development  of the dosage form, the choice of the route of administration and the dosage regimen, as well as the selection  of analytical methods for analyzing the quality of the finished dosage form and the effective, high-precision  determination of the content of the active substance and its likely decay products.<\/jats:p>","DOI":"10.18097\/pbmc20206603257","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T12:03:15Z","timestamp":1593172995000},"page":"257-264","source":"Crossref","is-referenced-by-count":0,"title":["The development of the physicochemical characteristics of the new original nootropic substance TST-9"],"prefix":"10.18097","volume":"66","author":[{"given":"G.E.","family":"Brkich","sequence":"first","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.V.","family":"Pyatigorskaya","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.V.","family":"Beregovykh","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.A.","family":"Zyryanov","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.B.","family":"Demina","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.O.","family":"Bakrushina","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7443","published-online":{"date-parts":[[2020]]},"reference":[{"key":"ref1","unstructured":"Hohlov A.L., Pyatigorskaya N.V. (2019) Promyshlennaya farmaciya. Put&apos; sozdaniya produkta, Moscow, 394 p."},{"key":"ref2","unstructured":"Ged Sh.K. (2008) Pharmaceutical Manufacturing Handbook: Regulations and Quality. A John Wiley & Sons, Inc."},{"key":"ref3","unstructured":"ICH Harmonised Tripartite Guidelineich Q8 \u201cPharmaceutical development\u201d. URL: http:\/\/gmp-compliance.org\/guidemgr\/files\/3-1-16.pdf. Data base 23.03.2020."},{"key":"ref4","unstructured":"Am Ende D.J. (2014) Production of drugs. Chemical technology from R&D to production. Cambridge Press."},{"key":"ref5","unstructured":"ICH Q6A Guidelines \u201cSpecifications: Analytical Procedures and Acceptance Criteria for New Drugs and Drugs \u2014 Chemicals\u201d. URL: http:\/\/gmp-compliance.org\/guidemgr\/files\/3-1-16.pdf. Data base 23.03.2020."},{"key":"ref6","unstructured":"Beregovyh V.V. (2018) Rukovodstva ICH dlya farmacevticheskoj otrasli. Mezhdisciplinarnye rukovodstva \u2013 COP \u201cProfessiya\u201d, Sankt-Peterburg, 416 p."},{"key":"ref7","unstructured":"State Pharmacopoeia of the Russian Federation, XIV edition, 2018."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Reshenie Soveta Evrazijskoj ekonomicheskoj komissii ot 03.11.2016 \u211677 \u201cOb utverzhdenii Pravil nadlezhashchej proizvodstvennoj praktiki Evrazijskogo ekonomicheskogo soyuza\u201d.","DOI":"10.15360\/1813-9779-2015-1-77-79"},{"key":"ref9","unstructured":"Reshenie Soveta Evrazijskoj ekonomicheskoj komissii ot 03 noyabrya 2016 goda \u211678 \u201cO Pravilah registracii i ekspertizy lekarstvennyh sredstv dlya medicinskogo primeneniya\u201d."},{"key":"ref10","unstructured":"Reshenie Kollegii Evrazijskoj ekonomicheskoj komissii ot 07.09.2018 \u2116151 \u201cOb utverzhdenii Rukovodstva po sostavleniyu normativnogo dokumenta po kachestvu lekarstvennogo preparata\u201d."},{"key":"ref11","unstructured":"Pyatigorskaya N.V. et al. (2018) Vestnik Rossijskoj Akademii Medicinskih Nauk, \u21163. p. 181-189."},{"key":"ref12","unstructured":"Krasnyuk I.I., Demina N.B., Anurova M.N., Solov&apos;eva N.L. (2019) Biofarmaciya, ili osnovy farmacevticheskoj razrabotki, proizvodstva i obosnovaniya dizajna lekarstvennyh form, M., GEOTAR-Media."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Lavrov M.I., Karlov D.S., Palyulin V.A., Grigoriev V.V., Brkich G.E., Pyatigorskaya N.V., Zapolski M.E. (2018) Mendeleev Communication, 28(3), 311-313.","DOI":"10.1016\/j.mencom.2018.05.028"},{"key":"ref14","unstructured":"Zefirov N.S., Palyulin V.A., Lavrov M.I., Zapolsky M.E. (2013) patent RF # 2480470. Appl. 2011113043 from 06.04.2011; publ. 27.04.2013 in BI #12."},{"key":"ref15","unstructured":"Lavrov M.I. (2011) Dizajn i issledovanie novyh modulyatorovAMRA-receptorov. Diss kand. him. nauk, Moskva."},{"key":"ref16","unstructured":"Pyatigorskaya N.V., Brkich G.E., Lavrov M.I., Palyulin V.A. (2018) J. Pharm. Sci. Res., 10(5), 1103-1106."}],"container-title":["Biomeditsinskaya Khimiya"],"original-title":[],"language":"ru","deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T12:03:59Z","timestamp":1593173039000},"score":1,"resource":{"primary":{"URL":"http:\/\/pbmc.ibmc.msk.ru\/en\/article-en\/PBMC-2020-66-3-257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020]]},"published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.18097\/pbmc20206603257","relation":{},"ISSN":["2310-6905","2310-6972"],"issn-type":[{"value":"2310-6905","type":"electronic"},{"value":"2310-6972","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}